Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Indeed, why not ask DeGrado?
If anyone would know, I feel like he would?
It's high comedy to me when you start speaking in absolutes about things that IPIX mgmnt doesn't even have concrete answers to.
$15M for B-OM. Show your work.
Not 'underestimating' anything here either.
Familiar with the funding agreements currently in place?
I'm not 'estimating' anything with this company any longer. I've learned my lesson the hard way.
Leo needs an expedient path to revenue, not more dead-end dilution.
The only winner if he pursues B-OM is himself.
2yrs of a P3 and countless millions of $ in endless dilution isn't a 'path to revenue'. It's a path to dragging out his to-date undeserved salary.
B-UC requires a partner as well. We don't have the time or funding for a P3 for that either.
https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
It's B-covid or bust. There won't be anything left if there's no grant/partnership after this. I don't see anyone sticking around while a P3 is run here. Dead money on the shareholder-side.
To my knowledge, I don't believe us to have a financial agreement in place substantial enough to self-fund a P3 going in any direction.
I think the only way fwd is grant/partnership/sale
...AND... please don't underestimate the level of stupidity here. Bear in mind the background wielding the strategy.
Related to the article you referenced here:
Problem 1: IPIX / GMU have no animal-data related to anti-viral efficacy.
Question 1: article refers to 'Early Covid'... where our P2 is for patients 'hospitalized with respiratory distress but not yet requiring high-level respiratory support' -https://clinicaltrials.gov/ct2/show/NCT04784897?term=Brilacidin&cond=SARS-CoV2+Infection&draw=2&rank=1 is there a distinction to be made here related to severity and timeline?
Also of note, the article mentions:
Sure... where is Locust Walk?
Do you believe in The Accountant's ability to negotiate a deal for manufacturing and distro with an EU country? How about Russia? ...or any country for that matter? How'd that office lease-renewal negotiation turn out for him?
Praying for a sale. I'm ready for my 5yr nightmare with this company to end.
This EUA-talk based on 60 people being dosed with B for C is kind of a moon-shot.
IF we have truly amazing, incontrovertible biomarker data supporting the dosing in these patients, and IF the FDA truly believes there's an opportunity to deploy this reasonably, then MAYBE.
We've actually seen comparable or better preclinical results elsewhere with other various compounds, and there are other drugs that are coming out of P2's currently that have promise.
Preclinical doesn'tnecessarily translate to clinical results.
All we can do is wait at this point. All other indications are on hold... not much mention of any strategy going in any direction. Classic IPIX.
'Revenue of current SOC' isn't a valid comparison with development cost, sales/distro ability that IPIX lacks. IPIX is an Accountant with a PO box... not a pharma company. Best hope IMO is for a nod to synergistic efficacy and for Gilead to realize the benefit of an acquisition.
Based on what...? Your opinion?
Is that how the world works?
It would help others (and possibly yourself) if you wouldn't confuse 'manipulation' with dilution.
Here is the OS documentation for this past year alone (2020):
Jan 2020- OS 214M ~
30 Apr 2020- OS 267,408,840
31 May 2020 OS- 296,688,311
30 June 2020 OS- 328,317,492
14 Sept 2020 OS- 343,579,992
16 nov 2020 OS- 355,957,332
30 Nov 2020 OS- 357,616,780
31 Dec 2020 OS- 367,984,689
31 Jan 2021 OS- 390,861,713
10 Feb 2021 OS -418,069,575
31 March 2021 OS- 426,673,198
When I got in several years back, the OS was around 80M. Now we're at 426M. That's not 'manipulation' that's dilution. Downward pressure from Leo's financing mechanism selling shares into the market drives the price down. Simple.
Conspiracy theories are for people who don't understand how things work.
I don't recall specifics, but all relevant data can be found here:https://clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT02949388+OR+NCT02324335+OR+NCT02052388+OR+NCT03042702+OR+NCT04240223
My take on it is: bad management.
If you're economically challenged with a potentially great product, and if there's interest in your asset, then working with a potential partner/acquirer to deliver the data they'd like to see in order to facilitate a deal would seem to make sense.
Trying to prove B out across a bunch of different indications with minuscule trial sizes, instead of hyper-focusing on one and executing a deal seems to have been the preoccupation of Leo to date.
Shareholder dilution has been a concern from a long-term investor vantage. Shorter-term interests have potential with the Covid indication to possibly look forward to.
As the saying goes: 'Good science dies at the hands of bad management' all the time.
Strategy to manage funds while targeting a +P value to acquire a partner would have been my priority.
We'll see if 60 subjects in the Covid trial is sufficient enough to partner/sell.
...insufficient data from p2's
Trial sizes have been too small
They seem to be able to move faster than LeoPharma....
Also legitimate meetings, and an investor relations partition with questions answered: https://relieftherapeutics.com/investor-relations
(being incorporated in CH carries more strict regulations and oversight requirements though)
...and news today which should please shareholders immensely- https://relieftherapeutics.com/newsblog/relief-reports-that-its-u-s-collaboration-partner-has-announced-successful-commercial-formulation-for-aviptadil
I guess we'll have to see the PR from Leo in the coming weeks to learn more about what's going on with IPIX...
It always comes back to the time/money equation.
Agreed concerning a reformulation for use prophylactically (ease of use), but that's going to require another P1 with the reform, + another P2 which would put us likely another year-out I think (maybe longer)? All of that could've been run simultaneously through GMU who have the ability to manage aerosolized containment protocol with their BSL-3.
Not sure why this wouldn't have been done while we await P2-C results other than cost... which brings me back to the strategy questions this stuff always seems to highlight. What's the plan, Leo?!
I guess we'll see what happens post-topline. Hoping (praying) it's got a plan behind it and isn't just another PR event and nothing more.
An interesting comment from a virologist-friend a few months back related to anti-virals needing to be 100% effective as anti-virals, or they're 100% ineffective.
Requiring an extended dosing period in the COVID trial makes me feel like it's not close to 100% effective as an anti-viral. Concerning? Hopefully the other MOA's help in other ways somehow?
I haven't read through the materials yet, but more POC stuff from Leo is par for the course for this company. Paying himself almost $1M this year alone for what? More tests? 15yrs of this company 'running more tests'. This is what shareholders are getting for their investment? Dilution and testing? Testing that doesn't even apply to the real world nonetheless!
The reality is closer to: BP wants to see more data related to both UC & Colitis (all of IBD), because Leo's run a string of statistically meaningless 'trials' to date and none of them are conclusive enough to precipitate a deal.
COVID is the only thing cooking currently with near-term potential.
Hopefully someone (Locust Walk?) can connect on this indication. Otherwise others will get to market far sooner I believe.
The industry isn't hanging about while Leo fumbles around trying to figure out what to do next. There are loads of alternatives coming.
No need to Man'splain what's going on with IPIX to me, but thx.
If you're here to fund Leo's lifestyle and ride the ups and downs based on PR's, then sure, .60-.80 is great if your basis is $.05.
I'm a long and my only interest in this, if in fact it's a 'bio-tech' company, is to see a product partnered/licensed or to see the company acquired. My basis is around $1, and has been for around 5yrs. The longer this nonsense takes, the more it costs. Simple economics and math.
We need a deal, not more BS PR's. Action, not talk.
If this means the company sells for $600-800M on positive results, then great. It'll be more than it's been worth in the history of its existence and would also mean a far greater likelihood of a compound actually reaching commercialization than with The Accountant at the helm; given his 15yr track record and lack of credentials.
I still firmly believe it's going to take far more than 'results' for this to mean anything. Leo's inability to properly capitalize the company and make meaningful progress in any direction, has been our issue.
Statistically meaningless trial sizes have been ridiculously devaluing to-date. IF we get great results, we need an M&A of some sort and 'management' needs to be removed from the picture and real cash and a fast-tracked strategy need to be put in place.
This will continue to go nowhere on just PR's and a lack of comprehensive strategy beyond 'results and prayer'.
http://www.ipharminc.com/new-blog/2021/7/16/shareholder-alert-covid-19-trial-update-upcoming-antiviral-conferences-july-16-2021
July 16, 2021
Shareholder Alert: COVID-19 Trial, Upcoming Antiviral Conferences
Brilacidin
Dear Innovation Pharmaceuticals Shareholder,
We trust that everyone is aware of the recent warning from the World Health Organization (WHO) regarding the Delta variant of COVID-19 that is spreading quickly throughout the world. We encourage everyone to review a MarketWatch article from Thursday, July 15 (link below) that provides insight on the new variant and statistics on rising rates of COVID-19 diagnoses and deaths worldwide. In the words of the WHO, “The pandemic continues to evolve with four variants of concern dominating global epidemiology,” “the pandemic is nowhere near finished,” and there is a “strong likelihood for the emergence and global spread of new and possibly more dangerous variants of concern that may be even more challenging to control.”
Variants have been a concern of ours from the outset, which keeps us driving forward as quickly as possible to develop Brilacidin as a new antiviral drug to destroy the resilient coronavirus.
As we announced last month, enrollment was completed to our 120-patient Phase 2 clinical trial of Brilacidin for the treatment of moderate-to-severe COVID-19 in hospitalized patients. As such, we are now quickly approaching the last of the 60th day post treatment telephone follow-up visits with trial participants, which are scheduled to take place by the first week of August. As this important trial event nears, monitoring/ review/ data cleaning continues with close coordination between the data management and statistics groups to the goal of closure of the study database and output of study results.
The trial was a double-blind format, so no one at this point has any knowledge of the efficacy results for the groups – as to which patients received Brilacidin plus standard of care and which received standard of care alone. Per industry best practices, the complete data set from the trial will be verified to ensure integrity and then the unblinding process will begin. We greatly look forward to that day and, in the interim, remain hopeful that the trial will have met its efficacy and safety endpoints. There is clearly a desperate need for a new COVID-19 treatment and to have a potent drug ready for when the next viral outbreak inevitably occurs.
Upcoming Conferences: As previously released, independent research on Brilacidin’s in vitro broad-spectrum antiviral properties will be presented next week, at the American Society of Virology’s 40th Annual Meeting (ASV 2021), as well as in later August, at the U.S. Department of Defense-sponsored 2021 Military Health System Research Symposium. The Company will make available copies of the oral presentations the day after they are given. The Brilacidin findings discussed at these conferences are planned to be submitted for peer-review publication.
Link to MarketWatch article: https://www.marketwatch.com/story/u-s-covid-19-cases-more-than-double-in-two-weeks-as-delta-variant-spreads-fast-and-who-warns-pandemic-nowhere-near-finished-11626360879
Thank you for your continued support. Stay well.
Leo Ehrlich
Chief Executive Officer, Innovation Pharmaceuticals, Inc.
Moderna is an actual company staffed by humans.
LeoPharma is an accountant with a PO box so far...
'God' isn't saving us from Leo.
I feel like he's built this to plod along much in the same fashion as NNVC, bilking shareholders out of millions, while accomplishing little to nothing.
He had the opportunity to uplist, at a partial cost of greater oversight. He eschewed it, in favour of running statistically insignificant trials, paying himself millions in return, and doing nothing more than PR'ing the living sh*t out of the 'events'.
You're right in the '15 years of ineptitude', but I feel like it's intentional.
The only thing I don't understand is 'why'.
He's been connected with competent management, funding, etc, and has rejected all of it. That's the part I don't understand, given that he's got so many shares. He stands to benefit massively if this goes anywhere. So why not get out of the 'comfort zone' and make a run at it?
Maybe we'll see something (other than nothing) happen out of this whole Covid mess... but not holding my breath here.
I firmly believe it's going to take a license/M&A to move this. Nobody (literally) knows about the 'company', and the bio's of the 'staff' aren't credentials enough to carry us anywhere currently.
Wondering how this is going to impact B for C:
https://endpts.com/moderna-puts-a-seasonal-flu-vaccine-in-the-clinic-as-execs-hope-to-open-chapter-2-of-their-blockbuster-vaccine-story/
People have been questioning the Sputnik vaccine...
Here's what Nature had to report about it:
https://www.nature.com/articles/d41586-021-01813-2?utm_source=Nature+Briefing&utm_campaign=3808e4fcab-briefing-dy-20210706&utm_medium=email&utm_term=0_c9dfd39373-3808e4fcab-46110006
Where do you think Leo's business model came from?
...oh yeah... http://www.nanoviricides.com/pipeline.html
The company where he used to work and one of the longer-running biotech scams in recent history...
Virtually identical 'corporate structure' even.
You know what they say about how far apples fall from the tree and all.
Not a clue what 'GBL' means/is.
IPIX has zero 'influence' moving in any direction. Prove it to be otherwise.
My bet is: absolutely nothing happens with this B-for-COVID scenario with this company. Nobody even knows this company exists.
I'd desperately love it to be otherwise, but we have 15yrs of literally nothing happening other than statistically insignificant trials being run, a chronically underfunded company unable to broker any sort of meaningful deal, and a CEO who's running the show more akin to a PR company than a Pharmaceutical company. He and Jane areIPIX. There's no R&D, there's no manufacturing, distribution... nothing. Zero.
...Sure... How many grants have we rec'd to-date?
How many completed P2's do we have and for how many different indications?
How many signed deals does the company have for these and what's our revenue stream look like after 15yrs of this?
How many PR's about 'negotiating with/presenting at/in-conversation with' have we seen over the years? Who's netted compensation for these 'negotiations/presentations/etc'?
Notice a pattern here yet?
Biden invests $3B into antiviral development for Covid-19
https://endpts.com/biden-invests-3b-into-antiviral-development-for-covid-19/
Some interesting info from an email this morning from ETrade:
...literally the same old story, year after year.
That makes this a non-‘investment’ and more like a scam by definition, wouldn’t you say?
One guy gets rich while bilking shareholders out of hard-earned cash.
Who is 'they' ?
Aspire?
We're back to our daily dilution rate of around 1M shares of volume coming/going. Guessing Leo's greenlighted them to continue diluting the shit out of shareholders once again.
Dilution machine is cranked up apparently:
Jan 2020- OS 214M ~
30 Apr 2-2- OS 267,408,840
31 May 2020 OS- 296,688,311
30 June 2020 OS- 328,317,492
14 Sept 2020 OS- 343,579,992
16 nov 2020 OS- 355,957,332
30 Nov 2020 OS- 357,616,780
31 Dec 2020 OS- 367,984,689
31 Jan 2021 OS- 390,861,713
10 Feb 2021 OS -418,069,575
31 March 2021 OS- 426,673,198
If Leo has cash on hand, why are shareholders still being diluted further into oblivion?
Still no mention of a plan moving forward with Anti-Viral indication beyond this P2. I understand the need to await results, but where is the B-IBD re-formulation update? B-OM?
Meet Ralph:
https://sph.unc.edu/adv_profile/ralph-s-baric-phd/
Oh I have.
It tells me that someone's lacking effective sales-means, or BizDev, and/or a product-of-interest.
We'll see what happens with this P2.
The clock is ticking.
J&J and their Anti-Viral move...
https://endpts.com/with-one-pandemic-still-raging-jj-bets-780m-on-a-potential-flu-therapy-for-the-next/
Things to consider when there are folks here saying IPIX is worth $20B or whatever, based on Brilacidin.
It's worth whatever the market says it's willing to pay.
Wonder what this means for relevancy IPIX... stuck in a lengthy P2?
I've sort of felt that the longer this takes, the less it's worth. I'll be shocked if we get to $1 just on positive P2 news. I feel like we need a massive partnership or M&A situation (or license) still.
https://endpts.com/humanigen-declares-win-in-severe-covid-19-delivering-much-needed-pandemic-weapon-and-vaulting-ahead-on-post-shkreli-turnaround/
This has been my concern for ages...
It may be less of an issue outside of this country, but w/o Leo having some sort of plan to move things forward across potentially many venues, I feel like this is gonna be more of a struggle than most on this board are willing to acknowledge. Not only do we have no cash, but no partners, etc, or even a grant. No mention of anything 'pan-corona' related in the CT protocol either, just COVID, which contradicts what's been said in PR's related to pan-corona/anti-viral applications of a broader-scope?
I've seen concerns related to the monoclonal antibody treatments being impaired efficacy-wise by the variants, which potentially bodes-well for Brilacidin, but maybe not if we don't even get to see IPIX data until the end of the summer. That's absurdly long and problematic across many fronts.
...it does when it's day-after-day, month-after-month, year after year.
Look at the IPIX 5yr chart for some insight and maybe overlay the OS for some more insight into what's really going on here...
Peer-comparo-wise, doesn't make things look much better either... Battle of the obscure, un-funded nano-cap bioTech's: https://seekingalpha.com/symbol/IPIX/peers/comparison
People keep comparing us to CYDY... here's the 5yr compare... which do you feel is the better investment? (ipix is orange)